Skip to main navigation

UNDERSTANDING THE BODY
- The Endocrine System
- The Menstrual Cycle
OUR SCIENCE
OUR FOCUS
OUR ADVOCACY
WHO WE ARE
- Our Purpose
- Our Leadership
JOIN THE TEAM
Investors & Media
Contact Us

Press Releases

Press Releases

Year

June 4, 2019

Myovant Sciences to Present at Upcoming June Investor Conferences

May 30, 2019

Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares

May 29, 2019

Myovant Sciences Announces $100 Million Public Offering of Common Shares

May 24, 2019

Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

May 14, 2019

Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids

May 13, 2019

Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids

March 5, 2019

Myovant Sciences to Present at Upcoming Investor Conferences

February 7, 2019

Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018

Toolkit

Print Page

RSS Feeds

Email Alerts

Contact

Search

UNDERSTANDING THE BODY
- The Endocrine System
- The Menstrual Cycle
OUR SCIENCE
OUR FOCUS
OUR ADVOCACY
WHO WE ARE
- Our Purpose
- Our Leadership
JOIN THE TEAM
Investors & Media
Contact Us

© 2019 Myovant Sciences Ltd. 2000 Sierra Point Parkway, 9th Floor, Brisbane, CA 94005 Terms of Use Privacy Policy Cookie Policy